SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-038678
Filing Date
2021-07-28
Accepted
2021-07-28 17:14:35
Documents
12
Period of Report
2021-07-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vktx-8k_20210728.htm   iXBRL 8-K 40290
  Complete submission text file 0001564590-21-038678.txt   170392

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vktx-20210728.xsd EX-101.SCH 5725
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vktx-20210728_lab.xml EX-101.LAB 19335
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vktx-20210728_pre.xml EX-101.PRE 11516
5 EXTRACTED XBRL INSTANCE DOCUMENT vktx-8k_20210728_htm.xml XML 3556
Mailing Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Business Address 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37355 | Film No.: 211123610
SIC: 2834 Pharmaceutical Preparations